Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Pelzer U, et al. Among authors: cubillo a. Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28. Br J Cancer. 2017. PMID: 28350787 Free PMC article. Clinical Trial.
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Among authors: cubillo a. Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1. Br J Cancer. 2013. PMID: 23907428 Free PMC article.
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Alvarez R, et al. Among authors: cubillo a. Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. Br J Cancer. 2014. PMID: 24642623 Free PMC article. No abstract available.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P. Van Cutsem E, et al. Among authors: cubillo a. Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9. Int J Cancer. 2018. PMID: 29756206 Clinical Trial.
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J. Fogelman D, et al. Among authors: cubillo a. Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19. Cancer Med. 2018. PMID: 30123970 Free PMC article. Clinical Trial.
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Hubner RA, et al. Among authors: cubillo a. Eur J Cancer. 2019 Jan;106:24-33. doi: 10.1016/j.ejca.2018.09.029. Epub 2018 Nov 17. Eur J Cancer. 2019. PMID: 30458340 Free article. Clinical Trial.
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Merle P, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Lancet Gastroenterol Hepatol. 2019. PMID: 30954567 Free article. Clinical Trial.
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
Taieb J, Seufferlein T, Reni M, Palmer DH, Bridgewater JA, Cubillo A, Prager GW, Vermeire A, Hédouin-Biville F, Teng Z, Macarulla T. Taieb J, et al. Among authors: cubillo a. BMC Cancer. 2023 Sep 18;23(1):877. doi: 10.1186/s12885-023-11377-1. BMC Cancer. 2023. PMID: 37723453 Free PMC article.
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B, Alcasid A, Zhang X, Van Cutsem E. Elez E, et al. Among authors: cubillo a. BMC Cancer. 2024 Apr 11;24(1):446. doi: 10.1186/s12885-024-12153-5. BMC Cancer. 2024. PMID: 38600471 Free PMC article. Clinical Trial.
93 results